PMV Pharmaceuticals (PMVP) · page 2 of 19
The slide highlights the high prevalence of p53 mutations (50-60%) and the specific Y220C mutation (1%) targeted by PMV, while noting the historical failure of similar approaches.
Research note · executive_summary · frame_problem · overcrowded density
Slide locked Sign in to view
Slide schematic 9/9
paragraph 7/7 source-note 1/1 title 1/1
Components 9
paragraph paragraph paragraph paragraph paragraph paragraph paragraph source-note headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.